Modular real-time technology and system integration enable instant decision-making
Berlinger’s unique modular real-time technology in combination with software integration now facilitate automated product stability evaluation through the tracking of the product across the entire supply chain. Product monitoring with a compatible and integrated system generates operational and cost-efficiencies, allows fast assessment of temperature excursions and scalability in a compliant way.
Klaus Kauer, Head of Quality Management & Responsible Person at Frigo-Trans, represented the commercial Pharma & Life Science segment, giving insights on how to scale and run a large-scale real-time monitoring operation would have been impossible without system integration.
Stefan Dürr, Senior Director of Product Management at IQVIA, is coming from the Clinical Supply Segment and shared his experiences on how it is possible, and what benefits it brings to be able to follow a product end-to-end, through all stages in the supply chain.
Based on market trends, interviews with industry stakeholders and evaluation of customer documentation, Berlinger identified and addressed three main areas that affect timely product release:
Passive monitoring solutions, local and disconnected systems as well as isolated data sets
Supply chain professionals within pharma are challenged with the task to identify cost-efficient solutions and build more resilient supply chains for increasingly temperature-sensitive and high-value products. Manual management of data across multiple software systems and monitoring solutions leads to errors, no immediate centralized oversight, data unavailability and multiplication. The consequences are non-conclusive reporting, extended product quarantine times, and in the worst-case, drug wastage. The inability to take immediate decision on the product stability status represents a quality and commercial risk and hinders pharmaceutical companies to scale rapidly.
With reference to the publication from McKinsey “Emerging from disruption: The future of pharma operations strategy”, the discussion focused on one of the four areas of strategic responses suggested by McKinsey: Digital - from targeted, single use cases to fully scaled and ready for ecosystem leadership.
“Emerging from disruption: The future of pharma operations strategy”, McKinsey 2023
In two use cases, Berlinger demonstrated how this can be achieved in cold chain monitoring through Modular Real-Time©, system integration and the ability to follow the product through the entire supply chain for immediate decision-making on product status.
The system integration allows Frigo-Trans scalability, increased the availability of data, timely availability of data as well as leads to increased accuracy of data for just-in-time decision making on product release. Klaus outlined in his presentation how the system integration delivered ROI within 24 hours due to increased quality, resilience, and employee effectiveness.
Berlinger plays a critical role in consolidating data sets from different partners and systems within the ecosystem of the clinical trial. “We reduced the timeline for managing temperature excursions from days to seconds”, Stefan stated. This data transparency supports the patient’s safety and therefore, the successful execution of the trial.
Marina Beer, Segment Manger Pharma & Life Sciences at Berlinger, shared how the new modular real-time technology as an integral part of the Berlinger SmartSystem brings value to the supply chain. The solution facilitates automation and real-time product visibility while decreasing costs by smart sharing of real-time communication capabilities. A unique feature of the SmartSystem platform is that each device is completely independent from the other, while all devices are storing the temperature data on the device, available for read-out even if no connectivity is provided.
The question to the audience on the status of their implementation of assessing the stability of their products based on end-to-end supply chain data yielded interesting results: 42% are already doing so, whereas 32% are not, but considering it and 26% are still assessing the stability of the product based on supply chain leg data.
Find out now, how modular real-time can be achieved by trying out a pilot or find out more about end-to-end stability budget evaluation, reach out to the Berlinger team.
► More information.